Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial

Abiraterone and enzalutamide are associated with side effects that may impair health-related quality of life (HRQoL). To assess patient-reported HRQoL, depression symptoms, and cognitive function for abiraterone versus enzalutamide. We randomized 202 patients in a phase II study of abiraterone versu...

Full description

Saved in:
Bibliographic Details
Published in:European urology 2019-06, Vol.75 (6), p.940-947
Main Authors: Khalaf, Daniel J., Sunderland, Katherine, Eigl, Bernhard J., Kollmannsberger, Christian K., Ivanov, Nikita, Finch, Daygen L., Oja, Conrad, Vergidis, Joanna, Zulfiqar, Muhammad, Gleave, Martin E., Chi, Kim N.
Format: Article
Language:English
Subjects:
Abiraterone
Aged
Aged, 80 and over
Androstenes - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cognitive function
Depression
Enzalutamide
Humans
Male
Metastatic castration-resistant prostate cancer
Neoplasm Metastasis
Phenylthiohydantoin - analogs & derivatives
Phenylthiohydantoin - therapeutic use
Prednisone - administration & dosage
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - pathology
Quality of Life
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abiraterone and enzalutamide are associated with side effects that may impair health-related quality of life (HRQoL). To assess patient-reported HRQoL, depression symptoms, and cognitive function for abiraterone versus enzalutamide. We randomized 202 patients in a phase II study of abiraterone versus enzalutamide for first-line treatment of metastatic castration-resistant prostate cancer (ClinicalTrials.gov: NCT02125357). Patients completed Functional Assessment of Cancer Therapy—Prostate (FACT-P) and Patient Health Questionnaire-9 (PHQ-9) questionnaires, and Montreal Cognitive Assessment (MoCA) cognitive assessments at baseline and on treatment. To compare the change in FACT-P scores over time between treatment arms, we used a mixed model for repeated measures (MMRM). For FACT-P domains where there was an interaction between the treatment arm and age, we constructed separate models for patients aged
ISSN:0302-2838
1873-7560
DOI:10.1016/j.eururo.2018.12.015